Co-founded by Professor Junying Yuan and Professor Jidong Zhu, two leading scientists in cell death and LLPS fields respectively;
• An integrated and experienced R&D team to support drug development from bench to bedside Liquid-liquid phase separation (LLPS) has been implicated in various diseases including cancer,neurodegenerative diseases, metabolic diseases, etc.;
• Our proprietary LLPS platform enables high throughput discovery of novel drugs targeting “undruggable” proteins such as transcription factors and phosphatases
• Various landmark papers including publication in Cell
• Leading asset is in Phase Ib;
• 3 assets in PCC nomination and IND enabling stage;
• Strategic collaboration with Roche and Lilly on LLPS platform established
• Clinical trial collaboration with MSD initiated
• An integrated and experienced R&D team to support drug development from bench to bedside Liquid-liquid phase separation (LLPS) has been implicated in various diseases including cancer,neurodegenerative diseases, metabolic diseases, etc.;
• Our proprietary LLPS platform enables high throughput discovery of novel drugs targeting “undruggable” proteins such as transcription factors and phosphatases
• Various landmark papers including publication in Cell
• Leading asset is in Phase Ib;
• 3 assets in PCC nomination and IND enabling stage;
• Strategic collaboration with Roche and Lilly on LLPS platform established
• Clinical trial collaboration with MSD initiated
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
SHP2, phase I ; ARV-7, IND enabling stage; YAP, IND enabling stage; other severals are at lead optimizaiton stage.
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
